Ion channels involved in stroke

Expert Opinion on Therapeutic Targets

Volumn 5, Issue 1, 2001, Pages 59-86

  Small, Daniel L ^a  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

Author keywords

apoptosis; calcium channels; cerebral ischaemia; excitotoxicity; GABA receptors; glutamate receptors; ion channels; metabotropic glutamate receptors; neuronal death; potassium channels; sodium channels

Indexed keywords

EID: 0009902065     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.5.1.59     Document Type: Review

References (281)

1. LARMJA, CHEUNG NS, BEARTPM:Apoptosisinduced via AMPA-selective glutamate receptors in cultured murine cortical neurons. J. Neurochem. (1997) 69:617-622.
2. MACMANUS JP, RASQUINHA I, BLACK MA et al.: Glutamate-treated rat cortical neuronal cultures die in away different from the classical apoptosis induced by staurosporine. Exp. Cell. Res. (1997) 233:310-320.
3. GWAG BJ, LOBNER D, KOH JY, WIE MB, CHOI DW: Blockade of glutamate receptors unmasks neuronal apoptosis after oxygen-glucose deprivation in vitro. Neuroscience (1995) 68:615-619.
4. CHEUNG NS, PASCOE CJ, GIARDINA SF, JOHN CA, BEART PM: Micromolar L-glutamate induces extensive apoptosis in an apoptotic-necrotic continuum of insult-dependent, excitotoxic injury in cultured cortical neurones. Neuropharmacology (1998) 37:1419-1429.
5. STRASSER U, FISCHER G: Quantitative measurement of neuronal degeneration in organotypic hippocampal cultures after combined oxygen/glucose deprivation. J. Neurosci. Meth. (1995) 57:177-186.
6. PULSINELLI WA, BRIERLEY JB: Anew model of bilateral hemispheric ischemia in the unanesthetized rat. Stroke (1979) 10:267-272.
7. SMITH ML, VON HANWEHR R, SIESJO BK: Models for studying long term recovery following forebrain ischemia in the rat. A 2-vessel occlusion model. Acta Neurol. Scand. (1984) 69:385-401.
8. GREEN AR, CROSS AJ: Techniques for examining neuroprotective drugs in vivo. Int. Rev. Neurobiol. (1997) 40:47-68.
9. MAEDA K, HATA R, HOSSMANN KA: Differences in the cerebrovascular anatomy of C57black/6 and SV129 mice. Neuroreport (1998) 9:1217-1219.
10. FUJII M, HARA H, MENG W, VONSATTEL JP, HUANG Z, MOSKOWITZ MA: Strain related differences in susceptibility to transient forebrain ischemia in SV-129 and C57black/6 mice. Stroke (1997) 28:1805-1810.
11. SMALL DL, BUCHAN AM: Animal models. Br. Med. Bull. (2000) 56:307-317.
12. MCAULEY MA: Rodent models of focal ischemia. Cerebvasc. Brain Metab. Rev. (1995) 7:153-180.
13. DUVERGER D, MACKENZIE ET: The quantification of cerebral infarction following focal ischemia in the rat: influence of strain, arterial pressure, blood glucose concentration and age. J. Cereb. Blood Flow Metab. (1988) 8:449-461.
14. OLNEY JW, HO OL: Brain damage in infant mice following oral intake of glutamate, aspartate or cysteine. Nature (1970) 227:609-611.
15. OLNEY JW: Kainic acid and other excitotoxins: a comparative analysis. Adv. Biochem. Psychopharmacol. (1981) 27:375-384.
16. OLNEY JW, LABRUYERE J, PRICE MT: Pathological changes induced in cerebrocortical neurons by phencyclindine and related drugs. Science (1989) 244:1360-1362.
17. SASAKI C, KITAGAWA H, ZHANG WR, WARITA H, SAKAI K, ABE K: Temporal profile of cytochrome c and caspase-3 immunoreactivities and TUNEL staining after permanent middle cerebral artery occlusion in rats. Neurol. Res. (2000) 22:223-228.
18. MACMANUS JP, BUCHAN AM: Apoptosis after experi mental stroke: fact or fashion? J. Neurotrauma (2000) 17:899-914.
19. BENVENISTEH, DREJERJ, SCHOUSBOEAetal: Elevation of the extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis. J. Neurochem.(1984) 43:1369-1374.
20. OBRENOVITCH TP, RICHARDS DA: Extracellular neurotransmitter changes in cerebral ischaemia. Cerebvasc. Brain Metab. Rev. (1995) 7:1-54.
21. SNYDER SH, FERRIS CD: Novel neurotransmitters and their neuropsychiatric relevance. Am. J. Psychiatry (2000) 157:1738-1751.
22. HARRIS EW: Subtypes of glutamate receptors: pharmacological classification. In: CNS Neurotransmitters and Neuromodulators Glutamate. Stone TW (Ed.), CRC Press, Bocat Raton, FL.USA (1995).
23. SMALL DL, BUCHAN AM: NMDA antagonists: their role in neuroprotection. Int. Rev. Neurobiol. (1997) 40:137-171.
24. DINGLEDINE R, BORGES K, BOWIED, TRAYNELIS SF:The glutamate receptor ion channels. Pharmacol. Rev. (1999) 51:7-61.
25. ROGAWSKI MA: Therapeutic potential of excitatory amino acid antagonists: channel blockers and 2,3-benzodiazepines. Trends Pharmacol. Sci. (1993) 14:325-331.
26. SIMON R, SHIRAISHI K: N-methyl-D-aspartate antagonist reduces stroke size and regional glucose metabolism. Ann. Neurol. (1990) 27:606-611.
27. TAKIZAWA S, HOGAN M, HAKIM AM: The effects of a competitive NMDA receptor antagonist (CGS-19755) on cerebral blood flow and pHin focal ischemia. J. Cereb. Blood Flow Metab. (1991) 11:786-793.
28. SAUER D, ALLEGRINI PR, COSENTI A, PATAKI A, AMACKER H, FAGG GE: Characterization of the cerebroprotective efficacy of the competitive NMDA receptor antagonist CGP 40116 in a rat model of focal cerebral ischemia: An in vitro magnetic resonance imaging study. J. Cereb. Blood Flow Metab. (1993) 13:595-602.
29. SAUER D, ALLEGRINI PR, FAGG GE: The competitive NMDA receptor antagonist CGP 40116 is a potent neuroprotectant in a rat model of focal cerebral ischemia. J. Neural Transm. (1994) 43:81-89.
30. BOAST CA, GERHARDT SC, PASTOR G, LEHMANN J, ETIENNE PE, LIEBMAN JM: The N-methyl-D-aspartate antagonists CGS 19755 and CPPreduce ischemic brain damage in gerbils. Brain Res. (1988) 442:345-348.
31. GROTTAJC, PICONE CM, OSTROW PTetal: CGS-19755,a competitive NMDA receptor antagonist, reduces calcium-calmodulin binding and improves outcome after global cerebral ischemia. Ann. Neurol. (1990) 27:612-619.
32. HASEGAWA Y, FISHER M, BARON BM, METCALF G: The competitive NMDA antagonist MDL-100,453 reduces infarct size after experimental stroke. Stroke (1994) 25:967-973.
33. ROBERTS-LEWIS JM, MARCY VR, YONGHUA Z, VAUGHT JL, SIMAN R, LEWIS ME: Aurintricarboxylic acid protects hippocampal neurons from NMDA-and ischemia-induced toxicity invivo. J.Neurochem. (1993) 61:378-381.
34. BULLOCH R, GRAHAM DI, CHEN MH, LOW D, MCCULLOCH J: Focal cerebral ischemia in the cat: pretreatment with a competitive NMDA receptor antagonist, D-CPPene.J. Cereb. Blood Flow Metab. (1990a) 10:668-674.
35. BULLOCH R, MCCULLOCH J, GRAHAM DI, LOWE D, CHEN MH, TEASDALE GM: Focal ischemic damage is reduced by CPPene studies in two animal models. Stroke (1990b) 21:III32-III36.
36. HERRLING PL: D-CPPene (SDZEAA494), a competitive NMDA antagonist: results from animal models and first results in humans. Neuropharmacology (1994) 10:S591.
37. SAUER D, WEBER E, LUOND G, DASILVA F, ALLEGRINI PR: The competitive NMDA antagonist CGP 40116 permanently reduces brain damage after middle cerebral artery occlusion in rats. J. Cereb. Blood Flow Metab. (1995) 15:602-610.
38. FERKANYJW, KYLEDJ, WILLETS J et al: Pharmacological profile of NPC 12626, a novel, competitive N-methyl-D-aspartate receptor antagonist. J. Pharmacol. Exp. Ther. (1989) 250:100-109.
39. NISHIKAWA T, KIRSCH JR, KOEHLER RC, MIYABE M, TRAYSTMAN RJ: Competitive N-methyl-D-aspartate receptor blockade reduces brain injury following transient focal ischemia in cats. Stroke (1994) 25:2258-2264.
40. ROMAN R, BARTKOWSKI H, SIMON R: The specific NMDA receptor antagonist AP-7 attenuates focal ischemic brain injury. Neurosci. Lett. (1989) 104:19-24.
41. SWAN JH, EVANS, MC, MELDRUM BS: Long-term development of selective neuronal loss and the mechanism of protection by 2-amino-7-phosphonoheptanoate in a rat model of incomplete forebrain ischaemia. J. Cereb. Blood Flow Metab. (1988) 8:64-78.
42. BLOCK GA, PULSINELLI WA: N-methyl-D-aspartate receptor antagonists: failure to prevent ischemia-induced selective neuronal damage. In: Cerebrovascular Diseases. ME Raichle WJ Powers (Eds). Raven Press, New York, USA (1987):37-42.
43. JENSEN ML, AUER RN: Intraventricular infusion of 2-amino-7- phosphonoheptanoate (APH) mitigates ischaemic brain damage. Neurol. Res. (1989)11:37-40.
44. SIMON RP, SWAN JH, GRIFFITHS T, MELDRUM BS: Blockade of N-methyl-D-aspartate receptors may protect against ischemic damage in the brain. Science (1984) 226:850-852.
45. FAVARON M, MANEV H, ALHO H et al: Gangliosides prevent glutamate and kainate neurotoxicity in primary neuronal cultures of neonatal rat cerebellum and cortex. Proc. Natl. Acad. Sci. USA(1988) 85:7351-7355.
46. OZYURTE, GRAHAM DI, WOODRUFF GN, MCCULLOCH J: Protective effect of the glutamate antagonist, MK-801, in focal cerebral ischemia in the cat.J. Cereb. Blood Flow Metab. (1988) 8:138-143.
47. PARK CK, NEHLS DG, GRAHAM DI, TEASDALE GM, MCCULLOCH J: The glutamate antagonist MK-801 reduces focal ischemic brain damage in the rat. Ann. Neurol. (1988a) 24:543-551.
48. PARK CK, NEHLS DG, GRAHAM DI, TEASDALE GM, MCCULLOCH J: Focal cerebral ischaemia in the cat: treatment with the glutamate antagonist MK-801 after induction of ischaemia. J. Cereb. Blood Flow Metab. (1988b) 8:757-762.
49. BIELENBERG GW, BECK T: The effects of dizocilpine (MK-801), phencyclidine and nimodipine on infarct size 48 h after middle cerebral artery occlusion in the rat. Brain Res. (1991) 552:338-342.
50. DEZSI L, GREENBERG JH, SLADKY J, ARAKI N, HAMAR J, REIVICH M: Prolonged effects of MK-801 in the cat during focal cerebral ischemia and recovery: survival, EEG activity and histopathology. J. Neurol. Sci. (1994) 121:110-120.
51. PERSSON L, HARDEMARK HG, BOLANDERHG, HILLERED L, OLSSON Y: Neurologic and pathologic outcome after middle cerebral artery occlusion in rats. Stroke (1989) 20:641-645.
52. WIELOCH T, GUSTAFSSON I, WESTERBERG E: Effects of the noncompetitive NMDA receptor antagonist MK-801 on ischemic and hypoglycemic brain damage. In: Frontiers in Excitatory Amino Acid Research, Vol. 46, Neurology and Neurobiology EA Cavalheiro, J Lehmann, L Turski (Eds.), Liss, New York, USA (1988):715-722.
53. FLEISCHER JE, TATEISHI A, DRUMMONDJC et al: MK-801, an excitatory amino acid antagonist, does not improve neurologic outcome following cardiac arrest in cats. J. Cereb. Blood Flow Metab. (1989) 9:795-804.
54. BUCHAN AM, PULSINELLI WA: Hypothermia but not the N-methyl-D-aspartate antagonist, MK-801, attenuates neuronal damage in gerbils subjected to transient global ischemia. J. Neurosci. (1990) 10:311-316.
55. LANIER WL, PERKINS WJ, KARLSSON BR et al: The effects of dizocilpine maleate (MK-801), an antagonist of the N-methyl-D-aspartate receptor, on neurological recovery and histopathology following complete cerebral ischemia in primates. J. Cereb. Blood Flow Metab. (1990) 10:252-261.
56. GILL R, FOSTER AC, WOODRUFF GN: Sytemic admini stration of MK-801 protects against ischemia-induced hippocampal neurodegeneration in the gerbil. J. Neurosci. (1987) 7:3343-3349.
57. GILL R, FOSTER AC, WOODRUFF GN: MK-801 is neuroprotective in gerbils when administered during the post-ischaemic period. Neuroscience (1988) 25:847-855.
58. SAUER D, NUGLISCH J, ROSSBERG C: Phencyclidine reduces postischemic neuronal necrosis in rat hippocampus without changing blood flow. Neurosci. Lett. (1988) 91:327-332.
59. MINEMATSU K, FISHER M, LI L et al.: Effects of a novel NMDA antagonist on experimental stroke rapidly and quantitatively assessed by diffusion weighted MRI. Neurol. (1993) 43:397-403.
60. KEANNA JFW, MCBURNEY RN, SCHERZ MW et al.: Synthesis and characterization of a series of diarylgua-nidines that are noncompetitive N-methyl-D-aspartate recetor antagonists with neuroprotective properties. Proc. Natl. Acad. Sci. USA (1989) 86:5631-5635.
61. PARK CK, MCBURNEY RN, HOLT WF et al.: The dose-dependency of the antiischemic efficacy and of the side effects of a novel NMDA antagonist, CNS 1102. J. Cereb. Blood Flow Metab. (1993) 13 :S641.
62. GAMZU ER, MCBURNEY R: Cerestat (CNS1102)-preliminary results in stroke and TBI patients. Neuropsychopharmacol. (1994) 10:S592.
63. KATSUTA K, NAKANISHI H, SHIRAKAWA K, YOSHIDA K, TAKAGIK,TAMURAA: The neuroprotectiveeffectofthe novel noncompetitive NMDA antagonist, FR115427 in focal cerebral ischemia in rats. J. Cereb. Blood Flow Metab. (1995) 15:345-348.
64. NAKANISHI H, KATSUTA K, UEDA Y, SHIRAKAWA K, YOSHIDA K: Protective effect of FR115427 against hippocampal damage in gerbils. Jpn. J. Pharmacol. (1994) 64:189-193.
65. WARNER DS, MARTIN H, LUDWIG P, MCALLISTER A, KEANA JFW, WEBER E: In vivo models of cerebral ischemia: effects of parenterally administered NMDA receptor glycine site antagonists. J. Cereb. Blood Flow Metab. (1995) 15:188-196.
66. MUELLER AL, ARTMAN LD, BALANDRIN MF et al.: NPS 1506, a novel NMDA receptor antagonist and neuroprotectant. Review of preclinical and clinical studies. Ann. NY Acad. Sci. (1999) 890:450-457.
67. KENT TA, EISENBERG H, QUAST M, ANDERSON A, HILLMAN G, CAMPBELL G: Dextrorphan reduces infarct volume after middle cerebral occlusion in rats: a magnetic resonance imaging and histopathology study. J. Cereb. Blood Flow Metab. (1989) 9:S153.
68. STEINBERG GK, SALEH J, DELAPAZ R, KUNIS D, ZARNEGAR SR: Pretreatmentwiththe NMDAantagonist dextrorphan reduces cerebral injury after focal ischemia in rabbits. Brain Res. (1989a) 497:382-386.
69. STEINBERG GK, SALEH J, KUNIS D, DELAPAZ R, ZARNEGAR SR: Protective effect of N-methyl-D-apspa-rtate antagonists after focal cerebral ischemia in rabbits. Stroke (1989b) 20:1247-1252.
70. SWAN JH, MELDRUM BS: Protection by NMDA antagonists against selective cell loss following transient ischaemia. J. Cereb. Blood Flow Metab. (1990) 10:343-351.
71. ARONOWSKI J, WAXHAM MN, GROTTA JC: Neuronal protection and preservation of calcium/calmodulin-dependent protein kinase II and protein kinase C activity by dextrorphan treatment in global ischemia. J.Cereb. Blood Flow Metab. (1993) 13:550-557.
72. STEINBERG GK, SALEH J, KUNIS D: Delayed treatment with dextromethorphan and dextrorphan reduces cerebral damage after transient focal ischemia. Neurosci. Lett. (1988a) 89:193-197.
73. JENSEN MI, AUER RN: Ketamine fails to protect against ischaemic neuronal necrosis in the rat. Br. J. Anaesth. (1988) 61:206-210.
74. MARCOUX FW, GOODRICHJE,DOMINICK MA: Ketamine prevents ischemic neuronal injury. Brain Res. (1988) 452:329-335.
75. ROUSSEL S, PINARD E, SEYLAZ J: Kyurenate does not reduce infarct size after middle cerebral artery occlusion in spontaneously hypertensive rats. Brain Res. (1990) 518:353-355.
76. GERMANO IM, PITTS LH, MELDRUM BS, BARTKOWSKI HM,SIMON RP: Kynurenate inhibitionof cell excitation decreases stroke size. Ann. Neurol. (1987) 22:730-734.
77. STEINBERG GK, GEORGE CP, DELAPAZ R, SHIBATA DK, GROSS T: Dextromethorphan protects against cerebral injury following transient focal ischemia in rabbits. Stroke (1988b) 19:1112-1118.
78. CHEN HSV, PELLIGRINI JW, AGGARWAI SK et al.: Open channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity. J. Neurosci. (1992) 12:4427-4436.
79. ERDO SL, SCHAFER M: Memantine is highly potent in protecting cortical cultures against excitotoxic cell death evoked by glutamate and N-methyl-D-aspartate. Eur. J. Pharmacol. (1991) 198:215-217.
80. SEIF EL NASR M, PERUCHE B, ROSSBERG C, MENNEL HD, KRIEGLSTEIN J: Neuroprotective effect of memantine demonstrated in vivo and in vitro. Eur. J. Pharmacol. (1990) 185:19-24.
81. MUIR KW, LEES KR: Clinical experience with excitatory amino acid antagonist drugs. Stroke (1995) 26:503-513.
82. BENNAN PE, GRAHAM DI, LEES KR, MCCULLOCH J: Neuroprotective effect of remacemide hydrochloride in focal cerebral ischemia in the cat. Brain Res. (1994) 664:271-275.
83. PALMER GC, CREGAN EF, BIALOBOK P, SYDSERFF SG, HUDZIK TJ, MCCARTHY DJ: The low-affinity, use-dependent NMDA receptor antagonist AR-R 15896AR. An update of progress in stroke. Ann. NY Acad. Sci. (1999) 890:406-420.
84. ORDY JM, VOLPE B, MURRAY R et al: Pharmacological effects of remacemide and MK-801 on memory and hippocampal CA1 damage in the rat four-vessel occlusion (4-VO) model of global ischemia. In: The Role of Neurotransmitters in Brain Injury. MYT Globus, WD Dietrich (Eds.), Plenum Press, New York, USA (1992):83-92.
85. WASTERLAIN CG, ADAMS LM, HATTORI H, SCHWARTZ PH Felbamate reduces hypoxicischemic brain damage in vivo. Eur. J. Pharmacol. (1992) 212:275-278.
86. WARNER DS, MARTIN H, LUDWIG P, MCALLISTER A, KEANA JFW, WEBER E: In vivo models of cerebral ischemia: effects of parenterally administered NMDA receptor glycine site antagonists. J. Cereb. Blood Flow Metab. (1995) 15:188-196.
87. HALEY EC, JR: Glycine antagonists in neuroprotection-I (GAIN-I). Stroke (1997) 28:232.
88. BOJE KM, SKOLNICK P, RABER J, FLETCHER RT, CHADER G Strychnine- insensitive glycine receptors in embryonic chick retina: characteristics and modulation of NMDA of neurotoxicity. Neurochem. Int. (1992) 20:473-450.
89. VON LUBITZ DKJE, LIN RCS, MCKENZIE RJ, DEVLIN TM, MCCABE RT, SKOLNICK P: A novel treatment of global cerebral ischaemia with a glycine partial agonist. Eur. J. Pharmacol. (1992) 219:153-158.
90. GOTTIB, BENAVIDES J, MACKENZIEET, SCATTONB:The phamacotherapy of focal cortical ischaemia in the mouse. Brain Res. (1990) 522:290-301.
91. CARTER C, BENAVIDES J, LEGENDRE P et al: Ifenprodil and SL 82.0715 as cerebral antiischemic agents. II. Evidence for N-methyl-D-aspartate receptor antagonist properties.J.Pharmacol.Exp. Ther. (1988) 247:1222-1232.
92. GOTTI B, DUVERGER D, BURTIN D et al: Ifenprodil and SL 882.0715 as cerebral anti-ischaemic agents. I. Evidence for efficacy in models of focal cerebral ischaemia.J.Pharmacol.Exp. Ther. (1988) 247:1211-1221.
93. MENNITI FS, COLLINS MA, CHENARD BL, SHALABY IA, WHITE WF: CP-101,606, a potent and selective antagonist of forebrain NMDA receptors: in vitro neuroprotective activity. Soc. Neurosci. Abstr. (1995) 21:37.
94. XUE D, HUANG ZG, BARNES K, LESIUK HJ, SMITH KE, BUCHAN AM: Delayed treatment with AMPA, but not NMDA, antagonists reduces neocortical infarction. J. Cereb. Blood Flow Metab. (1994) 14:251-261.
95. BUCHAN AM, XUE D, HUANG ZG, SMITH KH, LESIUK H: Delayed AMPA receptor blockade reduces cerebral infarction induced by focal ischemia. NeuroReport (1991a) 2:473-476.
96. GILL R, HARGREAVES RJ, KEMP JA: The neuroprotective effect of the glycine site antagonist 3R-(+)-cis-4-methyl-HA966 (L-687,414) in a rat model of focal ischaemia. J. Cereb. Blood Flow Metab. (1995) 15:197-204.
97. SHEARDOWN MJ, NIELSON EO, HANSEN AJ, JACOBSEN P, HONORE T: 2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline: a neuroprotectant for cerebral ischaemia. Science (1990) 247:571-574.
98. SHEARDOWN MJ, SUZDAK PD, NORDHOLM L: AMPA, but not NMDA, receptor antagonist is neuroprotective in gerbil global ischaemia, even when delayed 24 h. Eur.J. Pharmacol. (1993) 236:347-353.
99. DIEMER NH, JOHANSEN FF, JORGENSEN MB: N-methyl-D-aspartate and non-N-methyl-D-aspartate antagonists in global cerebral ischemia. Stroke (1990) 21 :III39-III42.
100. DIEMER NH, JOHANSEN FF, JORGENSEN MB, SHEARDOWN M, HONORE T: Protection against ischaemic hippocampal CA1 damage in the rat with a new non-NMDA antagonist, NBQX. Acta Neurol. Scand. (1992) 86:45-49.
101. BUCHAN AM, LI H, CHO S, PULSINELLI WA: Blockade of the AMPA receptor prevents CA1 hippocampal injury following severe but transient forebrain ischemia in adult rats. Neurosci. Lett. (1991b) 132:255-258.
102. LE PEILLET E, ARVIN B, MONCADA C, MELDRUM BS: The non-NMDA antagonists, NBQX and GYKI 52466, protect against cortical and striatal cell loss following transient global ischaemia in the rat. Brain Res. (1992) 571:115-120.
103. NELLGARD B, WIELOCH T: Postischaemic blockade of AMPA but not NMDA receptors mitigates neuronal damage in the rat brain following transient severe cerebral ischaemia. J. Cereb. Blood Flow Metab. (1992) 12:2-11.
104. PULSINELLI WA, CHO S: Blockade of the AMPAreceptor beginning 8 hours after transient forebrain ischaemia attenuates CA1 hippocampal injury in rats. Neurology (1992) (Suppl. 3):532S.
105. LI H, BUCHAN AM: Treatment with an AMPA antagonist 12 hours following severe normothermic forebrain ischemia prevents CA1 neuronal injury. J. Cereb. Blood Flow Metab. (1993) 13:933-939.
106. SCHEILKE GP, KUPINA NC, BOXER PA, CORDON JJ, BIGGE CF, MARCOUX FW: Delayed treatment with the novel AMPAreceptor antagonist, PD152247 (PNQX), reduces lesion size following focal ischemia and reperfusion in the rat. J. Cereb. Blood Flow Metab. (1995) 15:S372.
107. YATSUGI S, TAKAHASHI M, KAWASAKI-YATSUGI S et al.: Neuroprotective effect of YM90K, a novel AMPA/kainate receptor antagonists, in focal cerebral ischemia in cats. J. Cereb. Blood Flow Metab. (1996) 16:959-966.
108. SHIMIZU-SASAMATA M, KAWASAKIYATSUGI S, OKADA M et al: YM90K: phamacological characterization as a selective and potent alpha-amino-3-hydroxy- 5-methylisoxazole-4-propionate kainate receptor antagonistJ. Pharmacol. Exp. Ther. (1996) 276:84-92.
109. KAWASAKI-YATSUGI S, YATSUGI S, TAKAHASHI M et al: A novel AMPA receptor antagonist, YM872, reduces infarct size after middle cerebral artery occlusion in rats. Brain Res. (1998) 793:39-46.
110. KAWASAKI-YATSUGI S, ICHIKI C, YATSUGI S et al: Neuroprotective effects of an AMPAreceptor antagonist YM872 in a rat transient middle cerebral artery occlusion model. Neuropharmacology (2000) 39:211-217.
111. TAKAHASHI M, NI JW, KAWASAKI-YATSUGI S et al: Neuroprotective efficacy of YM872, an alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor antagonist, after permanent middle cerebral artery occlusion in rats. J. Pharmacol. Exp. Ther. (1998) 287:559-566.
112. GILL R, LODGE D: Pharmacology of AMPA antagonists. Int. Rev. Neurobiol. (1997) 40:197-232.
113. FRANK I, BRUHN T, DIEMER NH: The effect of an AMPA antagonist (NBQX) on postischaemic neurone loss and protein synthesis in the rat brain. Exp. Brain Res. (1993) 95:70-76.
114. SMITH SE, MELDRUM BS: Cerebroprotective effect of a non-N-methyl-D- aspartate antagonist, GYKI 52466, after focal ischemia in the rat. Stroke (1992) 23:861-864.
115. LEVAY DE: Stroke Treatment with Ancrod Trial (STAT). Stroke (1999) 30:234.
116. CHIAMULERA C, ALBERTINI P, VALERIO E, REGGIANI A: Activation of metabotropic receptors has a neuroprotective effect in a rodent model of focal ischaemia. Eur. J. Pharmacol. (1992) 216:335-336.
117. MAGINN M, CALDWELL M, KELLY JP, LEONARD BE: The effect of 2-amino-3-phosphonopropionic acid (AP-3) in the gerbil model of cerebral ischaemia. Eur. J. Pharmacol. (1995) 282:259-262.
118. SMALL DL, MORLEY P, BUCHAN AM: Preclinical studies of glutamate receptor antagonists for the treatment of cerebral ischemia. In: Stroke Therapy: Basic, Preclinical and Clinical Directions. Miller LP (Ed.), Wiley-Liss, New York, USA (1999):65-99
119. DAVIS SM, ALBERS GW, DIENER HC, LEES KR, NORRIS J: Termination of acute studies involving selfotel treatment. ASSIST Steering Committee. Lancet (1997) 349:32.
120. DAVIS SM, LEES KR, ALBERS GW et al: Selfotel in acute ischemic stroke. Possible neurotoxic effects of an NMDA antagonist. Stroke (2000) 31:347-354.
121. MORRIS GF, BULLOCK R, MARSHALL SB, MARMAROU A, MAAS A, MARSHALL LF: Failure of the competitive N-methyl-D-aspartate antagonist Selfotel (CGS 19755) in the treatment of severe head injury: results of two Phase III clinical trials. The Selfotel Investigators. J. Neurosurg. (1999) 91:737-743.
122. LEES KR: Cerestat and other NMDA antagonists in ischemic stroke. Neurology (1997) 49:S66-69.
123. RYAN M, RHÔNEY DH, LUER MS, HATTON J: New and investigational treatment options for ischemic stroke. Pharmacotherapy (1997) 17:959-969.
124. DYKER AG, LEES KR: Remacemide hydrochloride: a double-blind, placebo-controlled, safety and tolerability study in patients with acute ischemic stroke. Stroke (1999a) 30:1796-1801.
125. BRADFORD AP: IMAGES-intravenous magnesium efficacy in stroke trial IMAGES study group. Stroke (2000) 31:248.
126. MUIR KW, LEES KR: Dose optimization of intravenous magnesium sulfate after acute stroke. Stroke (1998) 29:918-923.
127. MUIR KW: New experimental and clinical data on the efficacy of pharmacological magnesium infusions in cerebral infarcts. Magnes. Res. (1998) 11:43-56.
128. STRAND T, WESTER PO: A double blind randomized pilot trial of magnesium therapy in acute cerebral infarction. 7 NordMeet Cerebrovasc. Dis. (1993):37.
129. SMALL DL, MORLEY P, BUCHAN AM: Glutamate receptor antagonists for the treatment of acute cerebral ischemia. In: Management of Acute Stroke Shuaib A, Goldstein LB (Eds.), Marcel Dekker, New York, USA (1999):341-361.
130. Synthelabo Reserche: Press Release, Paris, France (6 February 1996). FISHER M: Potentially effective therapies for acute ischemic stroke. Eur Neurol. (1995) 35:3-7.
131. CHENARD BL, MENNITI FS: Antagonists selective for NMDA receptors containing the NR2B subunit. Curr Pharm. Des. (1999) 5:381-404.
132. FISCHER G, MUTEL V, TRUBE G et al.: Ro 25-6981, a highly potent and selective blocker of N-methyl-D-aspartate receptors containing the NR2B subunit. Characterization in vitro. J. Pharmacol. Exp. Ther (1997) 283:1285-1292.
133. MERCHANT RE, BULLOCK MR, CARMACK CA et al: A double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of CP-101,606 in patients with a mild or moderate traumatic brain injury. Ann. NY Acad. Sci. (1999) 890:42-50.
134. ZHOU ZZL, CAI SX, WHITTEMORE ER et al.: 4-Hydroxy-1-[2-(4-hydroxyphenoxy) ethyl]-4-(4-meth ylbenzyl)pip. A novel, potent and selective NR1/2B NMDA receptor antagonist. J. Med. Chem. (1999) 42:2993-3000.
135. TANIGUCHI K, SHINJO K, MIZUTANI M et al.: Antinociceptive activity of CP-101,606, an NMDA receptor NR2B subunit antagonist. Br. J. Pharmacol. (1997) 122:809-12.
136. FILLHARD JA, SERPA KA, KINSORA JJ, MELTZER LT: The effects of Cl-1041 in two tests of analgesia: acetic acid-iduced writhing test and formalin foot pad test. Soc. Neurosci. Abstr. (2000) 26:617.
137. BLANCHET PJ, KONITSIOTIS S, WHITTEMORE ER, ZHOU ZL, WOODWARD RM, CHASE TN: Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl- tetrahydropyridine monkeys. J. Pharmacol. Exp. Ther. (1999) 290:1034-1040.
138. WRIGHT JL, GREGORY TF, BIGGE CF et al: Subtype-selective N-methyl-D-aspartate receptor antagonists: synthesis and biological evaluation of 1-(arylal-kynyl)-4-benzylpiperidines. J. Med. Chem. (1999) 42:2469-2477.
139. WRIGHT JL, GREGORY TF, BOXER PA, MELTZER LT, SERPA KA, WISE LD: Discovery of subtype-selective NMDA receptor ligands: 4-benzyl-1- piperidinylalkynylpyrroles,pyrazoles and imidazoles as NR1A/2B antagonists. Bioorg. Med. Chem. Lett. (1999) 9:2815-2818.
140. SCHELKUN RM, YUEN PW, SERPA K et al: Subtype-selective N-methyl-D-aspartate receptor antagonists: benzimidazalone and hydantoin as phenol replacements. J. Med. Chem. (2000) 43:1892-1897.
141. WRIGHT JL, GREGORY TF, KESTEN SR et al: Subtype-selective N-methyl-D-aspartate receptor antagonists: synthesis and biological evaluation of 1-(heteroarylalknyl)-4-benzylpiperidines. J. Med. Chem. (2000) 43:3408-3419.
142. KRETSCHMER BD, KRATZER U, BREITHECKER K, KOCH M: ACEA 1021, a glycine site antagonist with minor psychotomimetic and amnestic effects in rats. Eur. J. Pharmacol. (1997) 331:109-116.
143. ALBERS GW, CLARK WM, ATKINSON RP, MADDEN K, DATA JL, WHITEHOUSE MJ: Dose escalation study of the NMDA glycine-site antagonist licostinel in acute ischemic stroke. Stroke (1999) 30:508-513.
144. DrugsR DLicostinel. ACEA 1021. (1999) 1:27-28.
145. XUE D, MIYAZAKI BK, DANIELL G, CHENG X, WOODWARD RM: Co-administration of probenecid with licostinel increases the steady state plasma level and reduces the minimum effective dose of neuroprotection in a rat model of transient focal ischemia. Soc. Neurosci. Abst.(1999) 25:234.
146. DYKER AG, LEES KR: Safety and tolerability of GV150526 (a glycine site antagonist at the N-methyl-D-aspartate receptor) in patients with acute stroke. Stroke (1999b) 30:986-992.
147. MEALING GA, LANTHORN TH, MURRAY CL, SMALL DL, MORLEY P: Differences in degree of trapping of low-affinity uncompetitive N-methyl-D-aspartic acid receptor antagonists with similar kinetics of block. J. Pharmacol. Exp. Ther. (1999) 288:204-210.
148. NIELSEN EO, VARMING T, MATHIESEN C et al: SPD 502: a water-soluble and in vivo long-lasting AMPA antagonist with neuroprotective activity. J. Pharmacol. Exp. Ther (1999) 289:1492-1501.
149. UMEMURA K, KONDO K, IKEDA Y et al: Pharmacokinetics and safety of the novel amino-3-hydroxy-5methylisoxazole-4-propionate receptor antagonist YM90K in healthy men. J. Clin. Pharmacol. (1997) 37:719-727.
150. KOHARA A, OKADA M, OHNO K et al: In vitro characterization of YM872: a selective, potent and highly water soluble AMPAreceptor antagonist. Soc. Neurosci. Abst. (1996) 22:1528.
151. SIMMONS RM, LI DL, HOO KH, DEVERILL M, ORNSTEIN PL, IYENGAR S: Kainate GluR5 receptor subtype mediates the nociceptive response to formalin in the rat. Neuropharmacology (1998) 37:25-36.
152. ANDERSON BA, HARN NK, HANSEN MM, HARKNESS AR, LODGE D, LEANDER JD: Synthesis and anticonvulsant activity of 3-aryl-5H-2,3-benzodiazephine AMPA antagonists. Bioorg.Med. Chem. Lett. (1999) 9:1953-1956.
153. PRATT J, JIMONET P, BOHME GA et al.: Synthesis and potent anticonvulsant activities of 4-oxo-imidazo[1,2-a]inden. Bioorg. Med. Chem. Lett. (2000) 10:2749-2754.
154. KONITSIOTIS S, BLANCHET PJ, VERHAGEN L, LAMERS E, CHASE TN: AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys. Neurology (2000) 54:1589-1595.
155. HURKO O, WALSH FS: Novel drug development for amyotrophic lateral sclerosis. J. Neurol. Sci. (2000) 180:21-28.
156. MONAGHAN DT, COTMAN CW: The distribution of [3H]kainic acid binding sites in rat CNS as determined by autoradiography. Brain Res. (1982) 252:91-100.
157. CONN PJ, PIN JP: Pharmacology and functions of metabotropic glutamate receptors. Ann. Rev. Pharmacol. Toxicol. (1997) 37:205-237.
158. NICOLETTI F, BRUNO V, COPANI A et al: Metabotropic glutamate receptors: a new target for the therapy of neurodegenerative disorders? Trends Neurosci. (1996) 19:267-271.
159. MILLER S, KESSLAK JP, ROMANO C, COTMAN CW: Roles of metabotropic glutamate receptors in brain plasticity and pathology. Ann. NY Acad. Sci. (1992) 757:460-474.
160. PELLICCIARI R, LUNEIA R, COSTANTINO G et al.: 1-Aminoindan-1,5- dicarboxylic acid: a novel antagonist at phospholipase C-linked metabotropic glutamate receptors.J. Med. Chem. (1995) 38:3717-3719.
161. TOMS NJ, ROBERTS PJ, SALT TE, STATON PC: Latest eruptions in metabotropic glutamate receptors. Trends Pharmacol. Sci. (1996) 17:429-435.
162. HENRICH-NOACK P, REYMANN KG: (1S,3R)-ACPD, a metabotropic glutamate receptor agonist, enhances damage after global ischaemia. Eur.J. Pharmacol. (1999) 365:55-58.
163. LAM AG, SORIANO MA, MONN JA, SCHOEPP DD, LODGE D, MCCULLOCH J: Effects of the selective metabotropic glutamate agonist LY354740 in a rat model of permanent ischaemia. Neurosci. Lett. (1998) 254:121-123.
164. BOND A, O'NEILL MJ, HICKS CA, MONN JA, LODGE D: Neuroprotective effects of a systemically active group II metabotropic glutamate receptor agonist LY354740 in a gerbil model of global ischaemia. Neuroreport (1998) 9:1191-1193.
165. RAUCA C, HENRICH-NOACK P, SCHAFER K, HOLLT V, REYMANN KG: (S)-4C3HPG reduces infarct size after focal cerebral ischemia. Neuropharmacology (1998) 37:1649-1652.
166. HENRICH-NOACK P, HATTON CD, REYMANN KG: The mGlu receptor ligand (S)-4C3HPG protects neurons after global ischaemia in gerbils. NeuroReport (1998) 9:985-988.
167. IVERSEN L, MULVIHILL E, HALDEMAN B et al: Changes in metabotropic glutamate receptor mRNA levels following global ischemia: increase of a putative presynaptic subtype (mGluR4) in highly vulnerable rat brain areas. J. Neurochem. (1994) 63:625-633.
168. GLOBUS MYT, BUSTO R, DIETRICH WD et al: Effect of ischemia on the in vivo release of striatal dopamine, glutamate and gamma-aminobutyric acid studied by intracerebral microdialysis. J. Neurochem. (1998) 51:1455-1464.
169. HAGBERG H, LEHMANN A, SANDBERG M et al: Ischemia-induced shift of inhibitory and excitatory amino acids from intra-and extra-cellular compartments.J. Cereb. Blood Flow Metab. (1985) 5:413-419.
170. HEVERS W, LUDDENS H: The diversity of GABAA receptors. Pharmacological and electrophysiological properties of GABAA channel subtypes. Mol Neurobiol (1998) 18:35-86.
171. LYDEN PD: Gamma-aminobutyric acid agonists for neuroprotection. In: Stroke Therapy: Basic, Preclinical and Clinical Directions. Miller LP (Ed.), Wiley-Liss, New York, USA (1999):101-130.
172. JOHANSEN FF, DIEMER NH: Enhancement of GABA neurotransmission after cerebral ischemia in the rat reduces loss of hippocampal CA1 pyramidal cells. Acta Neurol Scand. (1991) 84:1-6.
173. STERNAU LL, LUST WD, RICCI AJ et al: Role for gamma-aminobutyric acid in selective vulnerability in gerbils. Stroke (1989) 20:281-287.
174. SHUAIB A, MAZAGRI R, IJAZ S: GABAagonist 'muscimol' is neuroprotective in repetitive transient forebrain ischemia in gerbils. Exp. Neurol (1993) 123:284-288.
175. SMITH AL, HOFF JT, NIELSEN SL et al: Barbiturate protection in acute focal cerebral ischemia. Stroke (1974) 5:1-7.
176. LAL S, SHUAIB A, IJAZ S: Baclofen is cytoprotective to cerebral ischemia in gerbils. Neurochem. Res. (1995) 20:115-119.
177. MEIER E, DREJER J, SCHOUSBOE A: Inhibition by GABA of evoked glutamate release from cultured cerebellar granule cells. In: Glutamine, Glutamate and GABA in the Central Nervous System. Hertz L, Kvamme E, McGeer EG, Schousboe A (Eds.), Alan R Liss, New York, USA (1983):509-516.
178. MORRISETT RA, MOTT DD, LEWIS DV et al: GABA-B receptor-mediated inhibition of the N-methyl-D-aspartate component of synaptic transmission in the rat hippocampus. J. Neurosci. (1991) 11:203-209.
179. OLPE H-R, BAUDRY M, FAGNI L et al: The blocking action of baclofen on excitatory transmission in the rat hippocampal slice. J. Neurosci. (1982) 2:698-703.
180. GREEN AR, HAINSWORTH AH, JACKSON DM: GABA potentiation: a logical pharmacological approach for the treatment of acute ischaemic stroke. Neurophar-macol. (2000) 39:1483-1494.
181. SNAPE MF, BALDWIN HA, CROSS AJ et al: The effects of chlormethiazole and nimodipine on cortical infarct area after focal cerebral ischaemia in the rat. Neurosci-ence (1993) 53:837-844.
182. SHUIAB A, IJAZS, KANTHAN R: Chlomethiazole protects the brain in transient forebrain ischemia when used up to 4 h after the insult. Neurosci. Lett. (1995) 197:109-112.
183. CROSS AJ, JONES JA, BALDWIN HA et al: Neuroprotective activity of chlormethiazole following transient forebrain ischaemia in the gerbil. Br. J. Pharmacol (1991) 104:406-411.
184. WAHLGREN NG, RANASINHA KW, ROSOLACCI T et al: Chlomethiazole Acute Stroke Study (CLASS): results of a randomised controlled trial of chlomethiazole versus placebo in 1360 acute stroke patients. Stroke (1999a) 30:21-28.
185. WAHLGREN NG, BORNHOV S, SHARMA A et al: The Chlomethiazole Acute Stroke Study (CLASS): efficacy results in 545 patients classified as total anterior circulation syndrome (TACS). J. Stroke Cerebravasc. Dis. (1999b) 8:1-10.
186. BARBER PA, DEMCHUK AM, ZHANG J, BUCHAN AM: Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. ASPECTS Study Group. Alberta Stroke Programme Early CT Score. Lancet (2000) 355:1670-1674.
187. DUNCAN PW, LAI SM, KEIGHLEYJ: Defining post-stroke recovery: implications for design and interpretation of drug trials. Neuropharmacology (2000) 39:835-841.
188. STYS PK, WAXMAN SG, RANSOM BR: Na+-Ca2+exchanger mediates Ca2+ influx during anoxia in mammalian central nervous system white matter. Ann. Neurol (1991) 30:375-380.
189. STYS PK, WAXMAN SG, RANSOM BR: Ionic mechanism of anoxic injury in mammalian CNS white matter: Role of Na+ channels and Na+-Ca2+ exchanger. J. Neurosci. (1992) 12:430-439.
190. XIE Y, DENGLER K, ZACHARIAS E et al: Effects of the sodium channel blocker tetrodotoxin (TTX) on cellular ion homeostasis in rat brain subjected to complete ischaemia. Brain Res. (1994) 652:216-224.
191. BOENING JA, KASS IS, COTTRELL JE et al: The effect of blocking sodium influx on anoxic damage in the rat hippocampal slice. Neuroscience (1989) 33:263-268.
192. STYS PK, RANSOM BR, WAXMAN SG: Tertiery and quaternary local anesthetics protect CNS white matter from anoxic injury at concentrations that do not block excitability. J. Neurophysiol (1992) 67:236-240.
193. SMITH SE, MELDRUM BS: Cerebroprotective effect of lamotrigine after focal ischaemia in rats. Stroke (1995) 26:117-122.
194. GRAHAM SH, CHEN J, LAN J et al.: Neuroprotective effects of a use-dependent blocker of voltage dependent sodium channel, BW619C89, in rat middle cerebral artery occlusion.J. Pharmacol Exp. Ther. (1994) 269:854-859.
195. LEACH MJ, SWAN JH, EISENTHAL D et al: BW619C89, a glutamate release inhibitor, protects against focal cerebral ischaemic damage. Stroke (1993) 24:1063-1067.
196. WIARD RP, DICKERSON MC, BEEK O et al: Neuroprotective properties of the novel antiepileptic lamotrigine in a gerbil model of global cerebral ischemia. Stroke (1995) 26:466-472.
197. GILLAND E, MALGORZATA P-S, ANDINE P et al.: Hypoxic-ischaemic injury in the neonatal rat brain: effects of pre-and post-treatment with the glutamate release inhibitor BW1003C87. Dev. Brain Res. (1994) 83:79-84.
198. LEKIEFFRE D, MELDRUM BS: The pyrimidine-derivative, BW1003C87, protects CA1 and striatal neurons followingtransient severe forebrain ischaemia in rats. A microdialysis and histological study. Neuroscience (1993) 56:93-99.
199. PRATT J, RATAUD J, BARDOT F et al: Neuroprotective actions of riluzole in rodent models of global and focal ischaemia. Neurosci. Lett. (1992) 140:225-230.
200. WAHL F, ALLIX M, PLOTKINE M et al: Effect of riluzole on focal cerebral ischaemia in rats. Eur J. Pharmacol (1993) 230:209-214.
201. STRUZMANN JM, MIGNANI S, DEBARNOT F et al.: Pharmacological profile and neuroprotective activities of RP 66055, a riluzole derivative, in rodents. Soc. Neurosci. Abstr. (1993) 19:1647.
202. MALGOURIS C, BARDOT F, DANIEL M et al: Riluzole, a novel anti-glutamate prevents memory loss and hippocampal neuronal damage in ischaemic gerbils.J. Neurosci. (1989) 9:3720-3727.
203. DOBLE A: The pharmacology and mechanism of action of riluzole. Neurology (1996) 47:S233-S241.
204. MELDRUM BS: Pharmacology and mechanism of action of lamotrigine. In Lamotrigine-A New Advance in the Treatment of Epilepsy (Reynolds EH Ed), Royal Society of Medicine Services Ltd., London, UK (1993):5-14.
205. SPEDDING M, PAOLETTI R: IUPHAR classification of calcium channels and drugs modifying channel function. Pharmacol Rev. (1992) 44:363-376.
206. HESS P: Calcium channels in vertebrate cells. Ann. Rev. Neurosci. (1990) 13:337-356.
207. MILLER RJ: Voltage-sensitive Ca2+ channels. J. Biol Chem. (1992) 267:1403-1406.
208. GLOSSMAN H, FERRY DR, GOLL A et al: Calcium channels: introduction to their molecular pharmacology. In: Cardiovascular Effects of Dihydropyridine-type Calcium Antagonists and Agonists. Fleckenstein A, Van Bremen C, Grob R, Hoffmeister F (Eds.), Springer-Verlag, Berlin, Germany (1985):113-139.
209. CRIBBS LL, LEEJH, YANG J et al: Cloningand characteri zation of alpha1Hfrom human heart, a member of the T-type Ca2+ channel gene family. Circ. Res. (1998) 83:103-109.
210. PEREZ-REYES E, CRIBBS LL, DAUD A et al.: Molecular characterization of a neuronal low-voltage-activated T-type calcium channel. Nature (1998) 391:896-900.
211. TURNER TJ, ADAMS ME, DUNLAP K: Calcium channels coupled to glutamate release identified by omega-Aga-IVA. Science (1992) 258:310-313.
212. MURPHY TH, WORLEY PF, BARABAN JM: L-type voltage-sensitive calcium channels mediate synaptic activa-tionofimmediateearly genes. Neuron (1991) 7:625-635.
213. WESTENBROEK RE, AHLIJANIAN MK, CATTERALL WA: Clustering of L-type Ca2+ channels at the base of major dendrites in hippocampal pyramidal neurons. Nature (1990) 347:281-284.
214. BROWN CM, CALDER C, LINTON Cet al.: Neuroprotective properties of lifarizine compared with those of other agents in a mouse model of focal cerebral ischaemia. Br. J. Pharmacol. (1995) 115:1425-1432.
215. BIELENBERG GW, BURNIOL M, ROSEN R et al.: Effects of nimodipine on infarct size and cerebral acidosis after middle cerebral artery in the rat. Stroke 21:IV90-IV92.
216. HARAH, NAGASAWAH, KOGUREK: Nimodipine attenuates both ischaemia-induced brain oedema and mortality in a rat novel transient middle cerebral artery occlusion model. Acta Neurochirur. (1990) 51:251-253.
217. ALPS BJ, CALDER C, HASS WK et al.: Comparative protective effects of nicardipine, flunarizine, lidocaine and nimodipine against ischaemic injury in the hippocampusofthe Mongolian gerbil. Br. J. Pharmacol. (1998) 93:877-883.
218. BAILEY SJ, WOOD NI, SAMSON NA et al.: Failure of isradipine to reduce infarct size in mouse, gerbil and rat models of cerebral ischaemia. Stroke (1995) 26:2177-2183.
219. KAWAMURA S, YAUI N, SHIRASAWA M et al.: Att-877, a Ca2+ antagonist fails to reduce infarct size following rat middle-cerebral artery occlusion. Acta Neurol. Scand. (1993) 88:269-272.
220. BARONE FC, LYSKO PG, PRICE WJ et al.: SB201823-A antagonizes calcium currents in central neurons and reduces the effects of focal ischaemia in rats and mice. Stroke (1995) 26:1683-1690.
221. BARONE FC, PRICE WJ, JAKOBSEN P et al.: Pharmacological profile of a novel neuronal calcium channel blocker includes reduced cerebral damage and neurological deficits in rat focal ischaemia. Pharmacol. Biochem. Behav. (1994) 48:177-185.
222. BENHAM CD, BROWN TH, COOPER DG et al.: SB210823-A, a neuronal Ca2+ antagonist is neuropro-tective in two models of cerebral ischaemia. Neuropharmacology (1993) 32:1249-1257.
223. WOOD NI, BENHAM CD, BROWN TH et al.: The effects of SB 206284A, a novel calcium channel antagonist, in two species in a focal model of cerebral ischaemia. J. Cereb. Blood Flow Metab. (1995) 15:S384.
224. HUNTER AJ: Calcium channel antagonists: their role in neuroprotection. In: Neuroprotective Agents and Cerebral Ischaemia. Green AR, Cross AJ (Eds.), Academic Press, San Diego, CA, USA (1997):95-108.
225. JACEWICZ M, BRINT S, TANABE J et al.: Continuous nimodipine treatment attenuates cortical infarction in rats subjected to 24 hours of focal cerebral ischaemia. J. Cereb. Blood Flow Metab. (1990) 10:89-96.
226. HOGAN M, GJEDDE A, HAKIM AM: Nimodipine binding in focal cerebral ischaemia. Stroke (1990) 21:78-80.
227. MAGNONI MS, GOTONI S, BATTAINI F et al.: L-type calcium channels are modified in rat hippocampus by short-term experimental ischaemia. J. Cereb. Blood Flow Metab. (1988) 8:96-99.
228. MOHR JP, ORGOGOZO JM, HARRISON MJG et al.: Meta-analysis of oral nimodipine trials in acute ischemic stroke. Cerebrovasc. Dis. (1994) 4:197-203.
229. KASTE M, FOGELHOLM R, ERILA T et al.: Arandomized, double-blind, placebo-controlled trial of nimodipine in acute ischemic hemispheric stroke. Stroke (1994) 25:1348-1353.
230. HORN J, LIMBURG M, VERMEULEN M: Very early nimodipine use in stroke (VENUS). Stroke (1999) 30:243.
231. BUCHAN AM, GERTLER SZ, LI H et al.: A selective N-type Ca2+ channel blocker prevents CA1 injury 24h following severe forebrain ischaemia and reduces infarction following focal ischaemia. J. Cereb. Blood Flow Metab. (1994) 14:903-910.
232. TAKIZAWA S, MATSUSHIMA K, FUJITA F et al.: Aselective N-type calcium channel antagonist reduces extracellular glutamate release and infarct volume in focal cerebral ischaemia. J. Cereb. Blood Flow Metab. (1995) 15:611-618.
233. ZHAO Q, SMITH ML, SIESJO BK: The omega-conopeptide SNX-111, an N-type calcium channel blocker, dramatically ameliorates brain damage due to transient focal ischaemia. Acta Physiol. Scand. (1994) 150:459-461.
234. VALENTINO K, NEWCOMB R, GADBOIS T et al.: A selective N-type calcium channel antagonist protects against neuronal loss after global cerebral ischaemia. Neurobiology (1993) 90:7894-7897.
235. YAMADA K, TERAOKA T, MORITA S et al.: Omega-Conotoxin GVIA protects against ischemia-induced neuronal death in the mongolian gerbil but not against quinolinic acid-induced neurotoxicity in the rat. Neuropharmacology (1994) 33:251-254.
236. SPEDDING M: Sodium and calcium channel modulators in stroke therapy In: Stroke Therapy: Basic, Preclinical and Clinical Directions. LP Miller (Ed.), Wiley-Liss, Inc. (1999):157-193.
237. Investigational Drugs weekly highlights Elan progresses with ziconotide NDA. (2000) 10:6.
238. LINGENHOHL K, SMALL DL, MONETTE R et al.: Explora tion of P-type Ca2+ channels as drug targets for the treatment of epilepsy or ischemic stroke. Neurophar macology (1997) 36:107-13.
239. ASAKURA K, MATSUO Y, OSHIMA T et al.: Omega-agatoxin IVA-sensitive Ca(2+) channel blocker, alpha-eudesmol, protects against brain injury after focal ischemia in rats. Eur. J. Pharmacol. (2000) 394:57-65.
240. TANAKA K, NOGAWA S, NAGATA E et al: Effects of blockade of voltage-sensitive Ca(2+)/Na(+) channels by a novel phenylpyrimidine derivative, NS-7, on CREB phosphorylation in focal cerebral ischemia in the rat. Brain Res. (2000) 873:83-93.
241. CAMPBELL CA, BARONE FC, BENHAM CD et al: Charac terisation of SB-221420-A-a neuronal Ca(2+) andNa(+) channel antagonist in experimental models of stroke. Eur J. Pharmacol (2000) 401:419-428.
242. LAWSON K: Is there a role for potassium channel openers in neuronal ion channel disorders? Exp. Opin. Invest. Drugs (2000) 9:2269-2280.
243. COETZEE WA, AMARILLO Y, CHIU J et al: Molecular diversity of K+ channels. Ann. NY Acad. Sci. (1999) 868:233-285.
244. SIESJO BK: Pathophysiology and treatment of focal cerebral ischemia. Part I: Pathophysiology. J. Neurosurg. (1992) 77:169-184.
245. ZETTERSTROM TSC, VAUGHAN-JONES RD, GRAHAME-SMITH DG: Ashort period of hypoxia produces a rapid and transient rise in [K+]e in rat hippocampus in vivo which is inhibited by certain K+ channel blocking agents. Neuroscience (1995) 67:815-821.
246. DUCHEN MR: Effects of metabolic inhibition on the membrane properties of isolated mouse primary sensory neurons. J. Physiol (1990) 424:387-409.
247. BEN-ARIY: Effects of glebenclamide, a selective blocker of ATP-K+ channel, on anoxic response of hippocampal neurons. Pflugers Arch. (1989) 414:111-114.
248. BEN-ARI Y, KRNJEVIC K, CREPEL V: Activators of ATP-sensitive K+channels reduce anoxic depolarization in CA3 hippocampal neurons. Neuroscience (1990) 37:55-60.
249. XIE Y, ZACHARIAS E, HOFF P et al: Ion channel involvement in anoxic depolarization induced by cardiac arrest in rat brain. J. Cereb. Blood Flow Metab. (1995) 15:587-594.
250. YU SP, YEH CH, SENSI SL et al: Mediation of neuronal apoptosis by enhancement of outward potassium current. Science. (1997) 278:114-117.
251. YU SP, YEH CH, GOTTRON F, WANG X, GRABB MC, CHOI DW: Role of the outward delayed rectifier K+currentin ceramide-induced caspase activation and apoptosis in cultured cortical neurons. J. Neurochem. (1999) 73:933-941.
252. MONTAGUE JW, BORTNER CD, HUGHES FM JR, CIDLOWSKI JA: A necessary role for reduced intracellular potassium during the DNA degradation phase of apoptosis. Steroids (1999) 64:563-569.
253. HUGHES FM JR, CIDLOWSKI JA: Potassium is a critical regulator of apoptotic enzymes in vitro and in vivo. Adv. Enzyme Regul. (1999) 39:157-171.
254. BORTNER CD, CIDLOWSKI JA: Caspase independent/dependent regulation of K(+), cell shrinkage and mitochondrial membrane potential during lymphocyte apoptosis. J. Biol. Chem. (1999) 274:21953-21962.
255. BORTNER CD, CIDLOWSKI JA: A necessary role for cell shrinkage in apoptosis. Biochem. Pharmacol. (1998) 56:1549-1559.
256. BORTNER CD, HUGHES FMJR, CIDLOWSKI JA:Aprimary role for K+ and Na+ efflux in the activation of apoptosis. J. Biol. Chem. (1997) 272:32436-32442.
257. HUGHES FM JR, BORTNER CD, PURDY GD, CIDLOWSKI JA: Intracellular K+ suppresses the activation of apoptosis in lymphocytes. J. Biol. Chem. (1997) 272:30567-30576.
258. GARCIA DE ARRIBA S, FRANKE H, PISSAREK M, NIEBER K, ILLES P: Neuroprotection by ATP-dependent potassium channels in rat neocortical brain slices during hypoxia. Neurosci. Lett. (1999) 273:13-16.
259. PISSAREK M, REICHELT C, KRAUSS GJ, ILLES P: Tolbutamide attenuates diazoxide-induced aggravation of hypoxic cell injury. Brain Res. (1998) 812:164-171.
260. WIND T, PREHN JH, PERUCHE B, KRIEGLSTEIN J: Activation of ATP-sensitive potassium channels decreases neuronal injury caused by chemical hypoxia. Brain Res. (1997) 751:295-299.
261. DOMOKI F, PERCIACCANTE JV, VELTKAMP R, BARI F, BUSIJA DW: Mitochondrial potassium channel opener diazoxide preserves neuronal-vascular function after cerebral ischemia in newborn pigs. Stroke (1999) 30:2713-2718.
262. PLAMONDON H, BLONDEAU N, HEURTEAUX C, LAZDUNSKI M: Mutually protective actions of kainic acid epileptic preconditioning and sublethal global ischemia on hippocampal neuronal death: involvement of adenosine A1 receptors and K(ATP) channels. J. Cereb. Blood Flow Metab. (1999) 19:1296-1308.
263. MALETIC-SAVATIC M, LENN NJ, TRIMMER JS: Differential spatiotemporal expression of K+ channel polypeptides in rat hippocampal neurons developing in situ and in vitro. J. Neurosci. (1995) 15:3840-3851.
264. LEWIS RS, CAHALAN MD: Potassium and calcium channels in lymphocytes. Ann. Rev. Immunol. (1995) 13:623-653.
265. NADEAU H, MCKINNEY S, ANDERSON DJ, LESTER HA: ROMK1 (Kir1.1) causes apoptosis and chronic silencing of hippocampal neurons. J. Neurophysiol. (2000) 84:1062-1075.
266. KOO GC, BLAKE JT, TALENTO A et al: Blockade of the voltage-gated potassium channel Kv1.3 inhibits immune responses in vivo. J. Immunol. (1997) 158:5120-5128.
267. KOO GC, BLAKE JT, SHAHK et al: Correolide and deriva tives are novel immunosuppressants blocking the lymphocyte Kv1.3 potassium channels. Cell Immunol. (1999) 197:99-107.
268. PONGS O, LEICHER T, BERGER M et al: Functional and molecular aspects of voltage-gated K channel beta subunits. Ann. NY Acad .Sci. (1999) 868:345-355.
269. HOFFMAN DA, MAGEE JC, COLBERT CM, JOHNSTON D: K+ channel regulation of signal propagation in dendrites of hippocampal pyramidal neurons. Nature (1997) 387:869-875.
270. AN WF, BOWLBY MR, BETTY M et al: Modulation of A-type potassium channels by a family of calcium sensors Nature. 2000, 403, 553-556.
271. YOUNG K, LIN S, SUN L et al: Identification of a calcium channel modulator using a high throughput yeast two-hybrid screen. NatureBiotechnol. (1998) 16:946-950.
272. NIEUWENHUIJSEN B, CAO J, RHODES K, YOUNG KH: Investigation of Kv4.3/KChip1 interations using a luciferas based yeast two-hybrid (YTH) system. Soc Neurosci. Abstr. (2000) 26:614.
273. GRIBKOFF VK, STARRETT JE, HEWAWASAM P et al: Targeting acute focal stroke with an opener ofMaxi-K potassium channels: BMS-204352 (MaxiPost). Soc. Neurosci. Abstr. (2000) 26:183.
274. MORLEY P, MACLEAN S, GENDRON TF et al: Pharmacological and molecular characterization of glutamate receptors in the MIN6 pancreatic beta-cell line. Neurol Res. (2000) 22:379-385.
275. GILL SS, MUELLER RW, MCGUIRE PF, PULIDO OM: Potential target sites in peripheral tissues for excitatory neurotransmission and excitotoxicity. Toxicol Pathol. (2000) 28:277-284.
276. GILL SS, PULIDO OM, MUELLER RW, MCGUIRE PF Immunochemical localization of the metabotropic glutamate receptors in the rat heart. Brain Res. Bull. (1999) 48:143-146.
277. GILL SS, PULIDO OM, MUELLER RW, MCGUIRE PF: Molecular and immunochemical characterization of the ionotropic glutamate receptors in the rat heart. Brain Res. Bull. (1998) 46:429-434.
278. GU Y, PUBLICOVER SJ: Expression of functional metabotropic glutamate receptors in primary cultured rat osteoblasts. Cross-talk with N-methyl-D-aspartate receptors. J. Biol. Chem. (2000) 275:34252-34259.
279. LAKETIC-LJUBOJEVIC I, SUVA LJ, MAATHUIS FJ, SANDERS D, SKERRY TM: Functional characterization of N-methyl-D-aspartic acid-gated channels in bone cells. Bone (1999) 25:631-637.
280. SHENG M, PAK DT: Ligand-gated ion channel interac tions with cytoskeletal and signaling proteins. Ann. Rev. Physiol. (2000) 62:755-778.
281. SATTLER R, XIONG Z, LU WY, HAFNER M, MACDONALD JF, TYMIANSKI M: Specific coupling of NMDA receptor activation to nitric oxide neurotoxicity by PSD-95 protein. Science (1999) 284:1845-1848.